4
CONSULTING AGREEMENT
THIS CONSULTING AGREEMENT (this "Agreement") is made and entered into
by and between CELSION CORPORATION, a Delaware Corporation, which has an address
of 00000-X Xxx Xxxxxxxx Xxxx, Xxxxxxxx, XX 00000-0000 ("Celsion"), and Xx. Xxxxx
X Xxxxxxxx, Social Security #000-00-000, a consultant, whose address is 00-00
Xxxxxxxx Xxxxxx, Xxxxxxxx Xxxx, XX 02467("Consultant") on October 1, 2003.
WHEREAS, Consultant specializes in the field of manufacturing and
supply chain management for medical devices with in-depth knowledge of the
manufacturing, supply and quality requirements of Boston Scientific Corporation
(BSC).
WHEREAS, Consultant advises on strategy formulation and implementation,
enhancing operational effectiveness, organizational development and management
coaching, and provides interim leadership as required.
WHEREAS, Celsion is transferring the production of its disposable BPH
Catheter Kits (Kits) from Catheter Research, Inc. (CRI) to an alternative
manufacturer acceptable to its distributor Boston Scientific Corporation.
WHEREAS, Celsion wishes to ensure that it is able to meet all of Boston
Scientific Corporation's supplier requirements and ship Catheter Kits from the
new supplier to Boston Scientific Corporation no later than June 25, 2004.
WHEREAS, Celsion, in order to ship Kits by June, 25 2004, expects by
April 16, 2003 to have completed transfer of manufacturing to an alternative
supplier and have completed a submission to the FDA for approval to change the
manufacturer
WHEREAS, Celsion through the process of changing the source supplier of
the Catheter Kit expects to generate a substantial reduction in the purchase
price of the Kits to meet a contractual BSC requirement that within 2 years from
initial sales to customers the purchase price shall be reduced by 50% from the
current price.
WHEREAS, Celsion has primary goal of systematic value enhancement
leading to a value realizing event in not more than 4 years and to achieve this
Celsion wishes to strengthen its strategy and implementation; and strengthen its
operational, organizational and management effectiveness
WHEREAS, Consultant is willing to advise and assist Celsion on the
basis set forth herein and for the consideration herein named.
NOW, THEREFORE, in consideration of the foregoing, of the mutual
promises of the parties hereto, and of other good and valuable consideration,
the receipt and sufficiency of which are hereby acknowledged, the parties
hereto, intending legally to be bound, hereby agree as follows:
2. Services to be Performed.
2.1 It is understood and agreed that Consultant implement and
manage a process to ensure that Celsion meets Boston Scientific
Corporation's requirements by June 25, 2004.
2.2 It is understood and agreed that consultant will provide
counsel on strategy, operational and organizational
effectiveness, organizational development, recruiting and
development of people, management coaching, ad hoc interim
leadership and other management consulting as required by
Celsion
2.3 It is anticipated that the Consultant will work any amount of
time necessary to provide the services agreed to herein
including full time (5 days per week) if required from October
1, 2003 though April 30, 2004 to complete transfer of
manufacturing and submission to the FDA by April 16, 2004.
2.4 Subsequent to April 30, 2004 Consultant will work an amount of
time as required by Celsion and agreed to by the Consultant
that is sufficient to provide the services itemized in 2.1 and
2.2. It is anticipated that this should average 2 days per week
3. Compensation. for the period October 11, 2003 through April 30, 2004
--------------------------------------------------------------------
Celsion shall compensate Consultant as follows:
3.1 Consultant shall be compensated at a rate of $1,600 per day
which amount shall be paid 70% in cash and 30% in shares of
Celsion common stock ("Celsion Shares").
Celsion will make cash payments within 10 days of submission of
an invoice by the Consultant. The amount of stock due in lieu
of cash will be calculated by multiplying the total
compensation (number of days worked multiplied by $1,600) by
30% and dividing the product of that calculation by the closing
price of Celsion `s stock on the last trading day of each
month. A stock certificate will be issued within 30 days of the
end of each quarter for the total number of Celsion Shares due
for the preceding quarter.
2
3.2 Consultant understands that the stock certificates, or other
instruments representing any of the Celsion Shares may bear
legends substantially similar to the following:
"The securities represented by this certificate have not been
registered under the Securities Act of 1933 or the securities
laws of any state and may not be sold or otherwise disposed
of except pursuant to an effective registration statement
under such act and applicable exemption to the registration
requirements of such act or such laws."
3.3 As an incentive to ensure that transfer of manufacturing and
submission to the FDA is completed by April 16, 2004 and that
approval of the alternate manufacturer by the FDA no later than
June 25, the Consultant will be eligible to receive a bonus of
$40,000, payable 50% in cash and 50% in shares of Celsion
common stock with a conversion price equal to the closing price
of Celsion common stock on April 30, 2004. In the event the
goal is not fully met the bonus shall be adjusted to an amount
mutually agreed upon by the Consultant and Celsion
3.4 Celsion will reimburse the Consultant for all out of pocket
expenses incurred in the performance of the obligations under
this agreement.
4 Compensation for the period subsequent to April 30, 2004
--------------------------------------------------------
Celsion shall compensate Consultant as follows:
4.1 Consultant shall be compensated at a rate of $13,600 per month
which amount shall be paid 70% in cash and 30% in shares of
Celsion common stock (Celsion Shares).
Celsion will make cash payments within 10 days of submission of
an invoice by the Consultant. The amount of stock due in lieu
of cash will be calculated by multiplying $13,600 by 30% and
dividing the product of that calculation by the closing price
of Celsion `s stock on the last trading day of each month. A
stock certificate will be issued within 30 days of the end of
each quarter for the total number of Celsion Shares due for the
preceding quarter.
4.2 This compensation shall be subject to the terms of 3.2 and 3.4
above
3
IN WITNESS WHEREOF, the parties hereto have hereunto affixed their signatures to
be effective as of the date and year first above written.
CONSULTANT CELSION CORPORATION
/s/Xxxxx X. Jacobson____________ By: /s/Xxxxxxx X. Deasey_________
-------------------------------- -----------------------------
Xxxxx X Xxxxxxxx Name: Xxxxxxx X. Xxxxxx
Consultant Title: Executive Vice President
4
